Johnson & Johnson quarterly sales rise 8.3pc, sees vaccine data "soon"

Johnson & Johnson on Tuesday posted an 8.3 per cent rise in quarterly sales and said it would share details from its keenly watched coronavirus vaccine trial soon, as the healthcare conglomerate races to develop a potential single-dose vaccine for COVID-19.

Quarterly sales rose to $22.48 billion from $20.75 billion.